Chargement en cours...
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
IMPORTANCE: Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation wit...
Enregistré dans:
| Publié dans: | JAMA Dermatol |
|---|---|
| Auteurs principaux: | , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5061067/ https://ncbi.nlm.nih.gov/pubmed/26222619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2015.1916 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|